Overactive Bladder (OAB) Therapeutics: Market Research Report

Date: August 22, 2011
Pages: 279
Price:
US$ 4,500.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OEA6CDD765FEN
Leaflet:

Download PDF Leaflet

Overactive Bladder (OAB) Therapeutics: Market Research Report
This report analyzes the worldwide markets for Overactive Bladder (OAB) Therapeutics in US$ Million.

The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

Also, a six-year historic analysis is provided for these markets.

The report profiles 34 companies including many key and niche players such as Allergan, Inc., Antares Pharma, Inc., Apogepha Arzneimittel GmbH, Astellas Pharma, Inc., Auxilium Pharmaceuticals, Inc., Kissei Pharmaceuticals Co., Ltd., KYORIN Pharmaceutical Co., Ltd., Novartis AG, Ono Pharmaceutical Co., Ltd., Ortho-McNeil-Janssen Pharmaceuticals, Inc., Pfizer, Inc., SALVAT Biotech, Sepracor Pharmaceuticals, Inc., and Watson Pharmaceuticals, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
1.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

2.INDUSTRY OVERVIEW

Outlook
Current & Future Analysis
Underdiagnosis – A Key Market Deterrent
Increasing Awareness- A Key to Success
Reaching Out to Urologists – A Key Strategy
Improved OAB Medications to Drive Growth
Ageing Population Reflect Significant market Opportunity

Table 1. Ageing (65+) Demographics as % of Total Population by Country (2000, 2010, 2025) (includes corresponding Graph/Chart)
Table 2. Prevalence (%) of Overactive Bladder Symptoms by Age (includes corresponding Graph/Chart)

Meager OAB Developmental Pipeline Deters Growth Prospects
Generics Stalls Revenues

3.COMPETITION

The Branded Drugs Landscape

Table 3. Sales of Major Overactive Bladder Drugs (2009) (In US$ Million) (includes corresponding Graph/Chart)

Review of Select Available Drugs
Detrol and Detrol LA (Tolterodine tartrate)
VESIcare® (solifenacin succinate)
SANCTURA® (trospium chloride)
Toviaz® (fesoterodine fumarate)
Enablex® (Darifenacin)
Ditropan and Ditropan XL (Oxybutynin chloride)
Oxytrol (Oxybutynin Patch)
The OAB Brand Matrix

4.URINARY INCONTINENCE - AN INSIGHT

How Does Normal Urinary Bladder Function?
What is Urinary Incontinence?
Male Incontinence
Women More Prone to Incontinency than Men
Incontinence Among Children
Types of Urinary Incontinence
Stress Incontinence
Urge Incontinence
Functional Incontinence
Overflow Incontinence
Mixed Incontinence
Reflex Incontinence
Transient Incontinence
Traumatic Incontinence

5.OVERACTIVE BLADDER

Definition
Types
By Incontinence
Overactive Bladder Dry
Overactive Bladder Wet
By Symptomatic Causes
Neurogenic OAB
Idiopathic OAB
Etiology
Symptoms
Impact of Overactive Bladder on Quality of Life
Diagnosis
Measurement of Postvoid Residual Urine
Cystoscopy
Uroflowmetry
Cystometry
Electromyography
Video Urodynamics
Treatment Options
Behavioral Remedies
Pharmacotherapy
Anticholinergic agents
Other Therapeutic Approaches
Device Therapy
Device Therapies in Men
Device and Minimally-Invasive Therapies in Women
Neuromodulation
Vaginal Devices
Collagen Injections
Retropubic Suspension
Sling Procedure
Midurethral Slings
Dietary Changes and Alternative Medicines

6.PRODUCT LAUNCHES/INTRODUCTIONS

Dr. Reddy’s Laboratories Launches Bispec
Watson Pharmaceuticals Introduces GELNIQUE™ (oxybutynin chloride) Gel 10%
Pfizer Launches TOVIAZ®

7.RECENT INDUSTRY ACTIVITY

Warner Chilcott Purchases US Rights of Enablex from Novartis
Serenity Pharmaceuticals and Allergan Enter Into Agreement
Astellas Pharma Applies for Approval of YM178 in Japan
Kyorin Pharmaceutical and Ono Pharmaceutical Independently File NDA
Endo Pharmaceuticals Purchases Indevus Pharmaceuticals
Allergan Signs Co-promotion Agreement with Quintiles Transnational
P&G Inks Agreement with Warner Chilcott
Astellas Pharma to Introduce Vesicare in China
Kyorin Pharmaceutical Inks Licensing Agreement with Eisai
Astellas Pharma Unveils Expansion Plans in India
Speciality European Pharma Obtains Distribution Rights to Regurin and Regurin XL
Toray and Taiho Pharmaceutical Enter into Alliance
Astellas Pharma Files Patent Infringement Lawsuit against Teva Pharmaceutical
Indevus Pharmaceuticals Inks License Agreement with Allergan
Asahi Kasei Obtains Intellectual Property Rights of Flivas from Roche Diagnostics

8.FOCUS ON SELECT GLOBAL PLAYERS

Allergan, Inc. (US)
Antares Pharma, Inc. (US)
Apogepha Arzneimittel GmbH (Germany)
Astellas Pharma, Inc. (Japan)
Auxilium Pharmaceuticals, Inc. (US)
Kissei Pharmaceuticals Co., Ltd. (Japan)
KYORIN Pharmaceutical Co., Ltd. (Japan)
Novartis AG (Switzerland)
Ono Pharmaceutical Co., Ltd. (Japan)
Ortho-McNeil-Janssen Pharmaceuticals, Inc. (USA)
Pfizer, Inc. (US)
SALVAT Biotech (Spain)
Sepracor Pharmaceuticals, Inc. (Canada)
Watson Pharmaceuticals, Inc. (US)

9.GLOBAL MARKET PERSPECTIVE

Table 4. World Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics by Country/Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 5. World Historic Review for Overactive Bladder Therapeutics by Country/Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Consumption in Thousand Metric Tons for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 6. World 15-Year Perspective for Overactive Bladder Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

10.THE UNITED STATES

A. MARKET ANALYSIS

Overview
Competition

Table 7. US Market for Overactive Bladder Therapeutics (2009): Percentage Share Breakdown by Drugs– Detrol/Detrol LA, Vesicare, Enablex, Generic Oxybutynin, Sanctura/Sanctura XR and Others (includes corresponding Graph/Chart)
Table 8. US Market for OAB Drugs: Prescription Share for Oral and Transdermal Medications

Patent Expiry of Select Overactive Bladder Drugs
Strategic Corporate Developments
Key Player Review

B. MARKET ANALYTICS

Table 9. The United States Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 10. The United States Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

11.JAPAN

A. MARKET ANALYSIS

Strategic Corporate Developments
Key Player Review

B. MARKET ANALYTICS

Table 11. Japanese Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 12. Japanese Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

12.EUROPE

A. MARKET ANALYSIS

Key Player Review

B. MARKET ANALYTICS

Table 13. European Past, Current & Future Market Analysis for Overactive Bladder Therapeutics by Country/Geographic Region – France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 14. European Historic Review for Overactive Bladder Therapeutics by Country/Geographic Region – France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 15. European 15-Year Perspective for Overactive Bladder Therapeutics by Country/Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

12A.FRANCE

Market Analysis

Table 16. French Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 17. French Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

12B.GERMANY

Market Analysis

Table 18. German Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 19. German Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

12C.ITALY

Market Analysis

Table 20. Italian Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 21. Italian Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

12D.THE UNITED KINGDOM

Market Analysis

Table 22. The UK Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 23. The UK Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

12E.REST OF EUROPE

Market Analysis

Table 24. Rest of Europe Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 25. Rest of Europe Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

13.REST OF WORLD

A. MARKET ANALYSIS

Strategic Corporate Developments

B. MARKET ANALYTICS

Table 26. Rest of World Recent Past, Current & Future Market Analysis for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2009 through 2017 (includescorresponding Graph/Chart)
Table 27. Rest of World Historic Review for Overactive Bladder Therapeutics with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Total Companies Profiled: 34 (including Divisions/Subsidiaries - 39)
Region/CountryPlayers
The United States
Canada
Japan
Europe
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Skip to top


Ask Your Question

Overactive Bladder (OAB) Therapeutics: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: